DOD Rare Cancers Idea Development Award | W81XWH 21 RCRP IDA

Opportunity Information: Apply for W81XWH 21 RCRP IDA

The DOD Rare Cancers Idea Development Award (FY21), offered through the Department of Defense (Department of the Army, U.S. Army Medical Research Acquisition Activity or USAMRAA), is a research funding opportunity designed to spark new, early-stage ideas that could open up fresh directions in rare cancer research. It focuses on generating impactful initial findings and creating new avenues of investigation rather than supporting mature, incremental projects. The overall intent is to back work that could meaningfully accelerate progress toward reducing, and ultimately eliminating, deaths and suffering caused by rare cancers.

A key feature of this award is its emphasis on conceptually innovative, high-risk/high-reward science. In practice, that means the program is looking for proposals that may be bold or unconventional but are grounded in a credible scientific framework and have the potential to produce major advances or critical discoveries. Projects should not simply refine existing approaches; they should aim to challenge assumptions, introduce novel strategies, or apply emerging concepts and technologies in ways that could reshape understanding, prevention, diagnosis, or treatment of rare cancers.

Applications are expected to be built around a well-formulated and testable hypothesis supported by a strong scientific rationale. Even though the research can be early in development, the proposal still needs to clearly define what will be tested, why it matters, and how the results could change the field. The program also requires preliminary data to demonstrate feasibility. Importantly, those preliminary data must include a disease-specific rationale and can include correlative findings from existing clinical trials or related studies. However, the preliminary data do not have to come directly from the exact rare cancer type or subtype being proposed, which gives applicants flexibility to leverage relevant evidence from adjacent cancers, platforms, or biological systems as long as the rationale convincingly supports translation to the target rare cancer context.

Administratively, the opportunity is listed as discretionary funding and may be made as either a grant or a cooperative agreement, indicating that some awards could involve more substantial involvement or coordination with the funding agency depending on project needs. The funding activity category is research and development (science and technology), and it is associated with CFDA number 12.420. Eligibility is described as unrestricted, meaning it is broadly open to a wide range of applicant organizations and entities, subject to any additional eligibility clarifications that may appear in the full announcement text. The opportunity was created on May 18, 2021, with an original application closing date of October 15, 2021. The announcement projected about 15 awards. The published award ceiling is listed as 0, which typically signals that a specific maximum dollar cap was not provided in the summary field and would need to be confirmed in the detailed solicitation documents.

Overall, this award targets investigators and teams who have a strong, scientifically reasoned idea for rare cancers that is still developing but ready to be tested, supported by feasibility evidence, and capable of producing the kind of early results that can catalyze larger breakthroughs or more definitive downstream studies.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Rare Cancers Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on May 18, 2021.
• Applicants must submit their applications by Oct 15, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 15 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 RCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: